Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.11 CAD | +4.46% | -5.38% | -21.85% |
Apr. 17 | NervGen Reports FY 2023 Net Loss of $0.38 Per Share, Provides Operations Update | MT |
Apr. 17 | NervGen Pharma Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 141M 103M |
---|---|---|---|---|---|
Net income 2024 * | - | Net income 2025 * | - | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 77.07% |
1 day | +4.46% | ||
1 week | -5.38% | ||
Current month | -4.09% | ||
1 month | +2.43% | ||
3 months | -20.97% | ||
6 months | +8.76% | ||
Current year | -21.85% |
Managers | Title | Age | Since |
---|---|---|---|
William Radvak
FOU | Founder | 61 | 17-01-18 |
Michael Kelly
CEO | Chief Executive Officer | 59 | 23-04-09 |
Bill Adams
DFI | Director of Finance/CFO | 62 | 20-02-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Randall Kaye
BRD | Director/Board Member | 62 | 20-10-27 |
Brian Bayley
BRD | Director/Board Member | 71 | 18-05-15 |
William Radvak
FOU | Founder | 61 | 17-01-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 2.11 | +4.46% | 83,425 |
24-04-25 | 2.02 | -3.35% | 117,470 |
24-04-24 | 2.09 | +1.46% | 100,296 |
24-04-23 | 2.06 | -3.29% | 54,702 |
24-04-22 | 2.13 | -4.48% | 75,350 |
Delayed Quote Toronto S.E., April 26, 2024 at 03:57 pm EDT
More quotesQuarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-21.85% | 103M | |
+1.51% | 42.59B | |
+8.57% | 40.65B | |
+49.22% | 40.57B | |
-12.36% | 26.77B | |
+8.92% | 24.81B | |
-25.13% | 18.17B | |
+29.17% | 12.05B | |
-3.12% | 11.7B | |
+6.35% | 11.1B |
- Stock Market
- Equities
- NGEN Stock